Medical Therapy for Advanced Pancreatic Cancer: Work in Progress
Downloads
References
Kang SP, Saif MW. Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP. J Pancreas (Online) 2008; 9:251-66. [PMID 18469437]
Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324:1457-61. [PMID 19460966]
Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009; 16:259-66. [PMID 19732725]
Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors. Cancer Res 1989; 49:6449-65. [PMID 2684393]
Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997; 3:177-82. [PMID 9018236]
Warburg O. On the origin of cancer cells. Science 1956; 123:309-314. [PMID 13298683]
Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis 2008; 29:1675-84. [PMID 18632755]
Khakoo AY, Sidman RL, Pasqualini R, Arap W. Does the rennin angiotensin system participate in regulation of human vasculogenesis and angiogenesis? Cancer Res 2008; 68:9112-5. [PMID 19010879]
Noguchi R, Yoshiji H, Ikenaka Y, Namisaki T, Kitade M, Kaji K, et al. Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via antiangiogenic activities. Oncol Rep 2009; 22:355-60. [PMID 19578777]
Amaya K, Ohta T, Kitagawa H, Kayahara M, Takamura H, Fujimura T, et al. Angiotensin II activates MAP kinase and NF-kappaB through angiotensin II type I receptor in human pancreatic cancer cells. Int J Oncol 2004; 25:849-6. [PMID 15375532]
Gong Q, Davis M, Chipitsyna G, Yeo CJ, Arafat HA. Blocking angiotensin II type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells. Pancreas 2010; 39:581-94. [PMID 20118823]
Pezzilli R, Corinaldesi R, Morselli-Labate A. Pancreatic cancer and cancer screening programs: from nihilism to hope. JOP. J Pancreas (Online) 2010; 11:654-5. [PMID 21068511]
Singh S, Srivastava SK, Bhardwaj A, Owen LB, Singh AP. CXCL12-CXCR4 signaling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. British J Cancer 2010; 103:1671-9. [PMID 21045835]
Fukamachi T, Chiba Y, Wanga X, Saito H, Tagawa M, Kobayashi H. Tumor specific low pH environments enhance the cytotoxicity of lovastatin and cantharidin. Cancer Lett 2010; 297:182-9. [PMID 20831979]
Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. British J Cancer 2010; 103:1644-8. [PMID 20978506]
Copyright (c) 2011 Raffaele Pezzilli, Roberto Corinaldesi, Antonio Maria Morselli-Labate
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.